OPKO Health (NASDAQ:OPK) Stock Price Up 3.3%

OPKO Health, Inc. (NASDAQ:OPK)’s share price rose 3.3% during trading on Wednesday . The stock traded as high as $1.25 and last traded at $1.25. Approximately 469,300 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 13,934,207 shares. The stock had previously closed at $1.21.

Analyst Ratings Changes

OPK has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research report on Wednesday, April 3rd. Barrington Research restated an “outperform” rating and set a $1.50 price target on shares of OPKO Health in a research note on Monday, April 1st. StockNews.com downgraded OPKO Health from a “hold” rating to a “sell” rating in a research note on Friday, March 1st. Finally, Piper Sandler restated an “overweight” rating and issued a $5.00 target price on shares of OPKO Health in a research note on Monday, April 1st.

OPKO Health Stock Up 1.2 %

The firm’s 50-day moving average is $1.06 and its 200-day moving average is $1.24. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.55 and a quick ratio of 1.22.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). The firm had revenue of $181.90 million for the quarter, compared to the consensus estimate of $177.53 million. OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. The business’s revenue was down 1.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.11) earnings per share. Sell-side analysts predict that OPKO Health, Inc. will post -0.33 EPS for the current year.

Insider Activity at OPKO Health

In related news, CEO Phillip Md Et Al Frost acquired 400,000 shares of the firm’s stock in a transaction on Thursday, January 18th. The stock was acquired at an average cost of $0.97 per share, for a total transaction of $388,000.00. Following the acquisition, the chief executive officer now owns 205,368,225 shares of the company’s stock, valued at $199,207,178.25. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, Director Richard M. Krasno acquired 30,000 shares of the stock in a transaction on Monday, January 29th. The stock was acquired at an average price of $0.99 per share, with a total value of $29,700.00. Following the completion of the transaction, the director now owns 103,333 shares of the company’s stock, valued at approximately $102,299.67. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Phillip Md Et Al Frost bought 400,000 shares of OPKO Health stock in a transaction dated Thursday, January 18th. The stock was acquired at an average cost of $0.97 per share, for a total transaction of $388,000.00. Following the completion of the transaction, the chief executive officer now directly owns 205,368,225 shares in the company, valued at $199,207,178.25. The disclosure for this purchase can be found here. Insiders have acquired a total of 5,030,000 shares of company stock worth $4,810,700 in the last 90 days. Company insiders own 47.26% of the company’s stock.

Institutional Trading of OPKO Health

Several hedge funds and other institutional investors have recently made changes to their positions in OPK. Vanguard Group Inc. boosted its stake in OPKO Health by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 39,751,293 shares of the biotechnology company’s stock worth $60,024,000 after purchasing an additional 428,520 shares in the last quarter. State Street Corp raised its holdings in OPKO Health by 56.7% in the 1st quarter. State Street Corp now owns 27,688,831 shares of the biotechnology company’s stock worth $95,250,000 after acquiring an additional 10,014,088 shares during the last quarter. Geode Capital Management LLC raised its holdings in OPKO Health by 3.9% in the 2nd quarter. Geode Capital Management LLC now owns 8,742,614 shares of the biotechnology company’s stock worth $18,971,000 after acquiring an additional 331,968 shares during the last quarter. Millennium Management LLC raised its holdings in OPKO Health by 318.6% in the 2nd quarter. Millennium Management LLC now owns 7,390,435 shares of the biotechnology company’s stock worth $18,698,000 after acquiring an additional 5,624,866 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in OPKO Health by 73.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 7,184,414 shares of the biotechnology company’s stock worth $24,717,000 after acquiring an additional 3,037,320 shares during the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.